No Picture
News

Halozyme Reports Second Quarter 2019 Results

– Total Revenues Increase 11% to $39.1 Million Compared to $35.2 Million in Prior-year Period — ENHANZE® Partner Janssen Submits Regulatory Applications for Subcutaneous Formulation of DARZALEX® in the U.S. and EU — Pivotal Phase 3 Trial Results from… […]

No Picture
News

Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2019 and Highlights Recent Corporate Progress

SAN DIEGO, May 9, 2019 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet pa… […]

No Picture
News

Halozyme Reports First Quarter 2019 Results

– Revenue of $56.9 Million Compared to $30.9 Million in Prior-year Period — ENHANZE® Partner Receives FDA Approval for Subcutaneous Formulation of Herceptin® — Positive Phase 3 Trial Results Announced for Subcutaneous Formulation of DARZALEX® — On … […]

No Picture
News

Ionis Exceeds 2018 Financial Guidance

Total revenue increased 17% compared to 2017 to $600 millionCommercial revenues more than doubledConference call and webcast today, February 27, 2019, at 11:30 a.m. Eastern Time

CARLSBAD, Calif., Feb. 27, 2019 /PRNewswire/ — Ionis Pharmaceuticals, I… […]

No Picture
News

Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2018 and Recent Corporate Progress

– Heron Raises Full-Year 2018 CINV Franchise Net Product Sales Guidance to $70 Million to $72 Million –

SAN DIEGO, Nov. 7, 2018 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the… […]